Biomolecular Medicine, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, Sir Alexander Fleming Building, South Kensington, London, SW7 2AZ, UK.
Pharmacogenomics. 2011 Jan;12(1):103-11. doi: 10.2217/pgs.10.157.
This article introduces and reviews the concept of pharmacometabonomics, with recent experimental exemplifications of the approach being described and discussed. Pharmacometabonomics seeks to predict the response of an individual to a stimulus (e.g., drug, toxin, surgery, nutrition and so on) prior to the stimulus or other perturbation. It is an integral part of top-down systems biology which aims to improve understanding of phenotypic differences and the impact of beneficial and pathological interventions. The pharmacometabonomic concept is also integral to the understanding of mammalian-gut microbiome cometabolic interactions and their consequences, including the impact on disease and therapy. Although the subject is only at an early stage and requires further exemplification and validation, the approach has major implications for improved efficiency in drug discovery efforts, for example, by enabling more careful selection of animals in preclinical studies, for better stratification of patients in drug clinical trials and for individualized therapies. It could also find application in population-wide large cohort studies and in studies of nutrition where it would allow the elucidation of health risk factors and provide easily measured surrogate biomarkers.
本文介绍并综述了药物代谢组学的概念，描述并讨论了该方法的最新实验例证。药物代谢组学旨在在刺激（例如药物、毒素、手术、营养等）或其他干扰之前预测个体对刺激的反应。它是自上而下的系统生物学的一个组成部分，旨在提高对表型差异以及有益和病理干预影响的理解。药物代谢组学的概念对于理解哺乳动物-肠道微生物群共代谢相互作用及其后果也很重要，包括对疾病和治疗的影响。尽管这一主题还处于早期阶段，需要进一步的例证和验证，但该方法对于提高药物发现工作的效率具有重要意义，例如，通过在临床前研究中更仔细地选择动物，在药物临床试验中更好地对患者进行分层，以及进行个体化治疗。它还可以应用于人群范围的大型队列研究和营养研究，从而可以阐明健康风险因素，并提供易于测量的替代生物标志物。
